2422-2423 / 2953
EORTC 22863: RT + concomitant and
adjuvant HT vs RT alone
Locally advanced prostate cancer
(T1-2, N0-X, M0 G3; T3-4, N0, M0, every G)
(n=415)
Randomized
Bolla M, et al. N Engl J Med 1997;337:295–300
Radiotherapy
(n=208)
(goserelin on progression)
Radiotherapy + goserelin (3.6 mg)
for 3 years
(n=207)
HT, hormone therapy; RT, radiotherapy